FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091749440> ?p ?o ?g. }

• W3091749440 endingPage "102542" @default.
• W3091749440 startingPage "102542" @default.
• W3091749440 abstract "Background Neuromyelitis optica spectrum disorder (NMOSD) is considered to be the most common subset of CNS inflammatory demyelinating diseases in China. We aimed to systematically evaluate the impact of NMOSD on Chinese patients’ quality of life (QoL), medical care experience, family wellness and social life. Methods A cross-sectional survey was performed involving 210 mostly AQP4-IgG-positive NMOSD patients from 25 provinces across China. An established survey instrument specific for NMOSD developed by The Guthy-Jackson Charitable Foundation and the Multiple Sclerosis Quality of Life-54 scale were implemented. Pearson or Spearman Correlation analysis was performed to define the significant determinants of QoL. Results More than 70% of the participants carried an initial diagnosis other than NMOSD, most of the patients were initially diagnosed with idiopathic optic neuritis (43.6%), multiple sclerosis (19.5%), gastrointestinal disorders (11.0%) and depression (10.0%). The average time elapsed between the first symptoms and accurate NMOSD diagnosis was 2.4 ± 4.9 years. Sixty-one percent of the participants reported NMOSD imposing a great negative impact on their life quality. NMOSD worsened both physical and emotional health (Short Form-36 physical health score: 37.9 ± 43.7, emotional health score: 44.8 ± 44.3). Visual impairment, pain, and bowel and bladder dysfunction were the greatest negative physical determinants of overall QoL. Worsened physical health was associated with diminished emotional health (r = 0.71, p < 0.001), and also with an interference in the ability to work (r = 0.41, p < 0.001). Only a small portion (3.3%) of the patients exhibited psychological resilience (with poor physical health but very robust emotional health). NMOSD significantly influenced the decision to have children in the study cohort, especially in the younger generation (r = -0.476, p < 0.001). Non-specific oral immunosuppressants were the most common preventive treatments, and only 13.9% received rituximab treatment. More than half (55.7%) of the patients reported dissatisfaction with current treatment options. A large proportion (88.1%) of the participants reported health insurance insufficient to pay all disease-related costs. Both concerns about treatment and about financial burden contributed to diminished QoL. Conclusions This investigation yields novel insights into the physical, emotional, and socioeconomic impact of NMOSD on Chinese patients, which may afford potentially modifiable aspects of personal or clinical care to improve the patients’ QoL, as well as serve as baseline data to reflect how future standard treatments will change patients’ life quality." @default.
• W3091749440 created "2020-10-08" @default.
• W3091749440 creator A5004309952 @default.
• W3091749440 creator A5008482365 @default.
• W3091749440 creator A5009098353 @default.
• W3091749440 creator A5015102287 @default.
• W3091749440 creator A5016570969 @default.
• W3091749440 creator A5021031438 @default.
• W3091749440 creator A5021299578 @default.
• W3091749440 creator A5045268007 @default.
• W3091749440 creator A5046359225 @default.
• W3091749440 creator A5047958767 @default.
• W3091749440 creator A5051862087 @default.
• W3091749440 creator A5071368345 @default.
• W3091749440 creator A5080400081 @default.
• W3091749440 creator A5080682084 @default.
• W3091749440 creator A5082241345 @default.
• W3091749440 creator A5083690679 @default.
• W3091749440 creator A5086664647 @default.
• W3091749440 date "2020-11-01" @default.
• W3091749440 modified "2023-10-17" @default.
• W3091749440 title "Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience" @default.
• W3091749440 cites W1983587796 @default.
• W3091749440 cites W1998609863 @default.
• W3091749440 cites W2119947320 @default.
• W3091749440 cites W2120238028 @default.
• W3091749440 cites W2129229339 @default.
• W3091749440 cites W2135174764 @default.
• W3091749440 cites W2177846153 @default.
• W3091749440 cites W2402573949 @default.
• W3091749440 cites W2463333245 @default.
• W3091749440 cites W2537017811 @default.
• W3091749440 cites W2549864631 @default.
• W3091749440 cites W2559206499 @default.
• W3091749440 cites W2604845570 @default.
• W3091749440 cites W2619381843 @default.
• W3091749440 cites W2783111346 @default.
• W3091749440 cites W2786513565 @default.
• W3091749440 cites W2887689171 @default.
• W3091749440 cites W2899876819 @default.
• W3091749440 cites W2924444286 @default.
• W3091749440 cites W2932668297 @default.
• W3091749440 cites W2933712812 @default.
• W3091749440 cites W2943416206 @default.
• W3091749440 cites W2945251361 @default.
• W3091749440 cites W2949643330 @default.
• W3091749440 cites W2955644700 @default.
• W3091749440 cites W2972221943 @default.
• W3091749440 cites W2984341132 @default.
• W3091749440 cites W2991438804 @default.
• W3091749440 cites W3018886418 @default.
• W3091749440 doi "https://doi.org/10.1016/j.msard.2020.102542" @default.
• W3091749440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33296965" @default.
• W3091749440 hasPublicationYear "2020" @default.
• W3091749440 type Work @default.
• W3091749440 sameAs 3091749440 @default.
• W3091749440 citedByCount "21" @default.
• W3091749440 countsByYear W30917494402021 @default.
• W3091749440 countsByYear W30917494402022 @default.
• W3091749440 countsByYear W30917494402023 @default.
• W3091749440 crossrefType "journal-article" @default.
• W3091749440 hasAuthorship W3091749440A5004309952 @default.
• W3091749440 hasAuthorship W3091749440A5008482365 @default.
• W3091749440 hasAuthorship W3091749440A5009098353 @default.
• W3091749440 hasAuthorship W3091749440A5015102287 @default.
• W3091749440 hasAuthorship W3091749440A5016570969 @default.
• W3091749440 hasAuthorship W3091749440A5021031438 @default.
• W3091749440 hasAuthorship W3091749440A5021299578 @default.
• W3091749440 hasAuthorship W3091749440A5045268007 @default.
• W3091749440 hasAuthorship W3091749440A5046359225 @default.
• W3091749440 hasAuthorship W3091749440A5047958767 @default.
• W3091749440 hasAuthorship W3091749440A5051862087 @default.
• W3091749440 hasAuthorship W3091749440A5071368345 @default.
• W3091749440 hasAuthorship W3091749440A5080400081 @default.
• W3091749440 hasAuthorship W3091749440A5080682084 @default.
• W3091749440 hasAuthorship W3091749440A5082241345 @default.
• W3091749440 hasAuthorship W3091749440A5083690679 @default.
• W3091749440 hasAuthorship W3091749440A5086664647 @default.
• W3091749440 hasConcept C118552586 @default.
• W3091749440 hasConcept C139719470 @default.
• W3091749440 hasConcept C142052008 @default.
• W3091749440 hasConcept C142724271 @default.
• W3091749440 hasConcept C159110408 @default.
• W3091749440 hasConcept C162324750 @default.
• W3091749440 hasConcept C1862650 @default.
• W3091749440 hasConcept C187212893 @default.
• W3091749440 hasConcept C2776572573 @default.
• W3091749440 hasConcept C2776867660 @default.
• W3091749440 hasConcept C2777154362 @default.
• W3091749440 hasConcept C2779951463 @default.
• W3091749440 hasConcept C2780640218 @default.
• W3091749440 hasConcept C2781137167 @default.
• W3091749440 hasConcept C71924100 @default.
• W3091749440 hasConceptScore W3091749440C118552586 @default.
• W3091749440 hasConceptScore W3091749440C139719470 @default.
• W3091749440 hasConceptScore W3091749440C142052008 @default.
• W3091749440 hasConceptScore W3091749440C142724271 @default.
• W3091749440 hasConceptScore W3091749440C159110408 @default.

• next